Last edition
News about "InvaGen Pharmaceuticals"
Cipla Partners with Qilu to Bring Pembrolizumab Biosimilar to US Market
Cipla and Qilu Pharmaceutical partner to commercialise QL2107, a pembrolizumab biosimilar, in the US, strengthening Cipla’s oncology and biosimilars portfolio.
Invagen Pharmaceuticals | 04/09/2026 | By News Bureau
Cipla's InvaGen Receives US FDA EIR for New York Manufacturing Facility
Cipla's subsidiary InvaGen has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (FDA), marking the successful closure of the inspection at its New York facility.
InvaGen Pharmaceuticals | 04/08/2026 | By News Bureau | 124
Bora Biologics Partners with Cipla Subsidiary to Manufacture NYPOZI at San Diego Facility
Bora Biologics has partnered with InvaGen Pharmaceuticals, a wholly owned subsidiary of Cipla Ltd., for the manufacture of NYPOZI at its FDA-registered facility in San Diego, California.
InvaGen Pharmaceuticals | 29/09/2025 | By Dineshwori | 383
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy